Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 8/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 8/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 3/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224749 | 0.80 | CHEK1 (0.44) | CHEK1MAP3K7TAB1AKT1AURKA | |
| SCHEMBL3285768 | 0.78 | CHEK1 (0.42) | CHEK1MAP3K7TAB1AKT1JAK3 | |
| SCHEMBL31618054 | 0.76 | CHEK1 (0.40) | CHEK1JAK3AURKA | |
| SCHEMBL13005543 | 0.76 | CHEK1 (0.40) | CHEK1JAK3AURKA | |
| SCHEMBL4780230 | 0.71 | CHEK1 (0.56) | CHEK1MAP3K7TAB1AKT1JAK2 | |
| SCHEMBL16765141 | 0.71 | CHEK1 (0.49) | CHEK1MAP3K7TAB1AKT1JAK2 | |
| SCHEMBL31658840 | 0.70 | AAK1 (0.31) | — | |
| SCHEMBL24345183 | 0.69 | CHEK1 (0.58) | CHEK1MAP3K7TAB1AKT1AURKA | |
| SCHEMBL2783376 | 0.68 | CHEK1 (0.53) | CHEK1MAP3K7TAB1AKT1JAK2 | |
| SCHEMBL20195284 | 0.68 | CHEK1 (0.49) | CHEK1MAP3K7TAB1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| EP-1660511-B1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2010-11-03 | — | — | EP | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | CHEK1 484/4885MAP3K7 1329/4885TAB1 2216/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | CHEK1 484/4885MAP3K7 1329/4885TAB1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.